TC BioPharm (Holdings)の空売り状況は、投資家がTC BioPharm (Holdings)の株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

TC BioPharm (Holdings) (NASDAQ:TCBP) 株価情報, 空売り情報

TC BioPharm (Holdings)

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings) PLC

WIIM

Hawaiian Electric shares are trading higher after the Hawaii Supreme Court clarified insurers' rights in the Maui wildfire litigation, aligning with the company and plaintiffs' positions.

LDOS

Leidos Holdings shares are trading higher after the company reported Q4 earnings and revenue above estimates.

COTY

Coty shares are trading lower after the company missed Q2 earnings and revenue estimates.

News

General

Redwire Bags Orion Space Solutions Contract To Deliver Mako Spacecraft For A US Space Force Space Systems Command Mission

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="3">For the month ended January 31, 2025</td>
<td colspan="3">For the month ended January 31, 2024</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="7">(dollars in millions)</td>
</tr>
<tr>
<td>End-of-period credit card and other loans</td>
<td>$</td>
<td>18,366</td>
<td>$</td>
<td>18,785</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Average credit card and other loans</td>
<td>$</td>
<td>18,530</td>
<td>$</td>
<td>18,915</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Year-over-year change in average credit card and other loans</td>
<td>(2</td>
<td>%)</td>
<td>(9</td>
<td>%)</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Net principal losses</td>
<td>$</td>
<td>123</td>
<td>$</td>
<td>128</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Net loss rate</td>
<td>7.8</td>
<td>%</td>
<td>8.0</td>
<td>%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="3">As of January 31, 2025</td>
<td colspan="3">As of January 31, 2024</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="7">(dollars in millions)</td>
</tr>
<tr>
<td>30 days + delinquencies – principal</td>
<td>$</td>
<td>1,032</td>
<td>$</td>
<td>1,170</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Period ended credit card and other loans – principal</td>
<td>$</td>
<td>16,874</td>
<td>$</td>
<td>17,311</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Delinquency rate</td>
<td>6.1</td>
<td>%</td>
<td>6.8</td>
<td>%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Bread Financial Sees Net Loss Rate Improve To 7.8% in January—Delinquency Rate Drops To 6.1% Year-Over-Year

Citigroup analyst Tyler Radke maintains ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) with a Sell and raises the price target from $8.5 to $9.

Price Target

Analyst Ratings

Citigroup Maintains Sell on ZoomInfo Technologies, Raises Price Target to $9

LSCC

Lattice Semiconductor shares are trading higher following mixed Q4 results.

Tech

DGHI

Digihost Forms Wholly-Owned Subsidiary, US Data Centers To Develop High-Performance Computing And AI-Tier Data Centers

AMKR

Amkor Technology shares are trading lower after the company missed Q4 revenue estimates.

Citigroup analyst Tyler Radke maintains Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) with a Buy and raises the price target from $14 to $22.

SMWB

Citigroup Maintains Buy on Similarweb, Raises Price Target to $22

Keybanc analyst Philip Gibbs upgrades Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) from Sector Weight to Overweight and announces $155 price target.

Upgrades

STLD

Keybanc Upgrades Steel Dynamics to Overweight, Announces $155 Price Target

Medicus Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) ("Medicus" or the "Company") today announced that it has entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, LTD (the "Investor"), an investment fund managed by Yorkville Advisors Global, LP. Pursuant to the SEPA, the Company has the option, at its sole discretion, to sell up to US$15,000,000 of the Company's common shares (the "Shares") to the Investor at any time during the 36-months following the date of the SEPA.
The Investor's obligation to purchase Shares is subject to a number of conditions, including that the Company file a registration statement with the Securities and Exchange Commission (the "SEC") registering the resale of the Shares issuable thereunder, and that the registration statement is declared effective by the SEC.
The total number of Shares issuable under the terms of the SEPA is limited to a number equivalent to 19.99% of the outstanding Shares as of the date of the SEPA unless certain pricing conditions are met, which could have the effect of limiting the total proceeds made available to the Company under the SEPA. The issuance of Shares under the SEPA is subject to further limitations, including that the Shares beneficially owned by the Investor and its affiliates at any one time will not exceed 4.99% of the then-outstanding Shares.
Shares issued and sold to the Investor under the SEPA will be priced at 97% of the Market Price (as defined in the SEPA) of the Shares during a specified three-day pricing period. The Company reserves the right to set a minimum acceptable price for the Share issuances.

MDCX

Medicus Pharma Secures $15M Equity Purchase Agreement With Yorkville Advisors

OESX

Orion Energy Sees FY25 Revenue Outlook Of Approximately 10% Growth, Expects Second Half Revenue To Be More Weighted To Q4

NCNO

nCino Acquires Sandbox Banking For $52.5M In Cash With Additional Earn-Out Up To $10M Based On Metrics

Citigroup analyst Tyler Radke maintains Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) with a Buy and raises the price target from $143 to $175.

SHOP

Citigroup Maintains Buy on Shopify, Raises Price Target to $175

2024 Production Results
<ul>
<li>Record quarterly copper production of 12,883 tonnes contributed to consolidated copper production for 2024 of 40,600 tonnes in concentrate.
<ul>
<li>The Caraíba Operations delivered 8,566 tonnes during the fourth quarter and 35,444 tonnes of copper in concentrate for the year, meeting revised 2024 production guidance.</li>
<li>Steady progress on increasing throughput volumes through year-end at the Tucumã Operation resulted in production of 4,317 tonnes during the fourth quarter and 5,156 tonnes of copper in concentrate for the year, below revised 2024 guidance.</li>
</ul>
</li>
<li>Gold production of 57,210 ounces at the Xavantina Operations was at the midpoint of original guidance and slightly below increased 2024 guidance.</li>
</ul>

Ero Copper Reports Record 2024 Copper Output Of 40,600 Tonnes—Projects Up To 85,000 Tonnes In 2025 With Major Growth Ahead

The Tetra-6 mission is a follow-on contract to the USSF/Air Force Research Laboratory (AFRL) Tetra-5 mission, for which Redwire is delivering two Mako spacecraft.

Contracts

Redwire Secures Follow-on Contract To Deliver Third Mako Spacecraft For US Space Force

Morgan Stanley analyst Matthew Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Equal-Weight and raises the price target from $450 to $459.

VRTX

Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $459

BHVN

Biohaven Announces FDA Acceptance And Priority Review Of Its New Drug Application For Troriluzole In Treatment Of Spinocerebellar Ataxia

Needham analyst Scott Berg maintains SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) with a Buy and lowers the price target from $230 to $210.

SPSC

Needham Maintains Buy on SPS Commerce, Lowers Price Target to $210

TC BioPharm (TCBP) announced that shareholders have formally approved the recently announced 25% stock dividend. TC BioPharm declared that last wee...

TC Biopharm shareholders approve 25% stock dividend

The latest update is out from TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ). TC BioPharm conducted a general meeting on December 30, 2024, w...

TC BioPharm Approves Key Resolutions to Enhance Strategic Flexibility

TC BioPharm (TCBP) has advanced negotiations with both of its previously aforementioned acquisition candidates. This past spring TCBP announced the...

TC Biopharm advances negotiations with acquisition candidates

The latest update is out from TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ). TC Biopharm has announced the approval and distribution of a sp...

TC Biopharm Announces Special Stock Dividend and Temporary Trading Halt

These are the upcoming stock splits for the week of January 6 to January 10, based on&nbsp;TipRanks' Stock Splits Calendar. A&nbsp;stock split&nbsp...

Upcoming Stock Splits This Week (January 6 to January 10) – Stay Invested

TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ) has provided an announcement. TC Biopharm (Holdings) Plc announced that it received a notifica...

TC Biopharm Faces Potential Nasdaq Delisting Due to Bid Price Non-Compliance

TC BioPharm to implement ADS ratio change

19:50 EST TC Biopharm (TCBP) (Holdings) PLC – ADR trading halted, news pending Published first on TheFly – the ultimate source for real-time, marke...

TC Biopharm (Holdings) PLC – ADR trading halted, news pending

TC BioPharm (TCBP) announced the first Cohort B patient in the ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 in Acute Myeloid Leukemia, has...

TC Biopharm completes initial Cohort B patient dosing in ACHIEVE trial

TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ) has shared an update. On February 5, 2025, TC BioPharm announced a change in its American Depo...

Comments

TC BioPharm (Holdings)

空売り

TC BioPharm (Holdings) (NASDAQ:TCBP) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル